PD-L1-inhibitor

PD-L1 inhibitor (抗 PD-L1 抗体)

一行要約

PD-L1 (CD274) に結合し PD-1 / B7.1 (CD80) との相互作用を阻害する monoclonal antibody class。NSCLC では (1) Stage III post-CRT consolidation の唯一の paradigm (Antonia et al. NEnglJMed 2017 PACIFIC、durvalumab)、(2) 1L IO + 化療 ± anti-VEGF (Socinski et al. NEnglJMed 2018 IMpower150)、(3) SCLC 1L IO + 化療 (Horn et al. NEnglJMed 2018 IMpower133 / Paz-Ares et al. Lancet 2019 CASPIAN)、(4) 周術期 NSCLC (Heymach et al. NEnglJMed 2023 AEGEAN)、(5) Adjuvant (Felip et al. Lancet 2021 IMpower010) で確立。Anti-PD-1 と作用機序は密接だが PD-L2 ↔ PD-1 への影響なし、ADCC / CDC profile が isotype 別に異なる。

メンバー比較表

薬剤	製品名	Isotype	主要試験	適応
Atezolizumab	Tecentriq	humanized IgG1 (Fc-engineered for low ADCC)	IMpower133 / 150 / 110 / 010	SCLC 1L、NSCLC 1L+chemo、TPS≥50% 単剤、adjuvant、TNBC、HCC
Durvalumab	Imfinzi	human IgG1κ (Fc-modified)	PACIFIC / CASPIAN / POSEIDON / AEGEAN	Stage III NSCLC consolidation、SCLC 1L、SCC、Mesothelioma、周術期
Avelumab	Bavencio	human IgG1 (ADCC retained)	JAVELIN Lung 100 / 101	NSCLC 限定 (陰性)、UC、Merkel cell
Sugemalimab	Cejemly	human IgG4	GEMSTONE-301 / 302 (中国)	中国 stage III consolidation、stage IV NSCLC

主要エビデンス

Stage III 切除不能 NSCLC consolidation (PD-L1 阻害剤の最大独自領域)

Antonia et al. NEnglJMed 2017 (PACIFIC、unresectable stage III NSCLC で同時 platinum-based CRT 後 1-42 日以内に PD なし、713 例) が durvalumab consolidation 12 か月 vs placebo を比較し、median PFS 16.8 vs 5.6 か月 (HR 0.52) を示した。OS update Antonia et al. NEnglJMed 2018 で 24-mo OS 66.3 vs 55.6%、HR 0.68 を確認、長期 Faivre-Finn et al. JThoracOncol 2021 が 4-yr OS 49.6 vs 36.3%、5-yr OS 42.9% に到達し、stage III に対する curative 化学放射線後の 唯一の global standard consolidation を確立した。post-discontinuation IO の影響を補正した Ouwens ELCC 2019 でも OS benefit は robust。

1L 進行 NSCLC IO + 化療 ± anti-VEGF

Socinski et al. NEnglJMed 2018 (IMpower150、非扁平 NSCLC 1202 例、ABCP = atezolizumab + bevacizumab + carboplatin + paclitaxel vs BCP) が ITT で median OS 19.2 vs 14.7 か月 (HR 0.78)、PFS 8.3 vs 6.8 か月 (HR 0.62) を達成し、EGFR / ALK driver+ TKI 後および肝転移症例でも benefit を示した点で他の 1L IO + 化療試験と差別化された。長期 Socinski et al. JThoracOncol 2021 と key-subgroup Nogami et al. JThoracOncol 2022 が EGFR / liver met benefit を再確認、Nogami et al. JThoracOncol 2022 が EGFR-mutant subset の OS HR 0.61 を示した。Atezolizumab + 化療単独は IMpower130 / 132 (Nishio et al. CancerSci 2021) と扁平の Jotte et al. JThoracOncol 2020 でも PFS / OS modest benefit を示した。Durvalumab + tremelimumab + 化療の POSEIDON は OS HR 0.77、durvalumab 単剤化療なしの MYSTIC (Rizvi et al. JAMAOncol 2020 / Rizvi et al. JAMAOncol 2020) は陰性で、bTMB (Si et al. ClinCancerRes 2021) を含むバイオマーカー探索が継続。

SCLC 1L IO + platinum/etoposide

Horn et al. NEnglJMed 2018 (IMpower133、ES-SCLC 403 例、carbo + etoposide ± atezolizumab) が median OS 12.3 vs 10.3 か月 (HR 0.70, p=0.007) で初の OS benefit を示し、長年 standard だった carboplatin/etoposide のみの治療を置き換えた。PD-L1 サブ解析・長期 Liu et al. JClinOncol 2021 で 3-yr OS 16% に到達。CASPIAN (Paz-Ares et al. Lancet 2019、805 例、platinum/etoposide ± durvalumab、OS HR 0.73) が durvalumab で同方向 benefit を確認、tremelimumab 上乗せ (Goldman et al. LancetOncol 2021) は OS HR 0.82 で statistical superiority に至らず、SCLC dual IO の限界を示した。

周術期 / Adjuvant NSCLC

Felip et al. Lancet 2021 (IMpower010、stage IB-IIIA 切除後 adjuvant 化療 → atezolizumab 1 年 vs BSC) が PD-L1 ≥1% subset で DFS HR 0.66 を示し、IO の adjuvant 設定での benefit を確立。周術期では Heymach et al. NEnglJMed 2023 (AEGEAN、neoadjuvant durvalumab + 化療 → 術後 durvalumab 12 cycles) が EFS HR 0.68、pCR 17.2 vs 4.3% を示し、CheckMate 816 (nivolumab) と KEYNOTE-671 (pembrolizumab) と並ぶ周術期 IO の選択肢に。

1L PD-L1 高発現 単剤

IMpower110 (atezolizumab vs 化療、PD-L1 high で OS HR 0.59) が PD-L1 阻害剤でも 1L 単剤の選択肢を提供。日本での adverse event 解析 Socinski et al. JAMAOncol 2023 が irAE-efficacy 関連を IMpower 系列 pooled で確認している。

メカニズム

PD-L1 細胞外 IgV-like ドメインに結合し PD-1 / B7.1 (CD80) との engagement を阻害。Anti-PD-1 と異なり PD-L2 ↔ PD-1 経路には影響しない ため、PD-L2 主導の immune homeostasis (特に肺) への影響が理論的に少ないとされ、pneumonitis 発症率が anti-PD-1 より低いという観察的データがある。Fc isotype:

• IgG1 backbone (Avelumab) : ADCC 機能保持で PD-L1 高発現腫瘍細胞の depletion 効果も有するが、PD-L1+ T 細胞の depletion で逆効果の懸念あり。NSCLC では JAVELIN Lung 100/101 が陰性で標準化に至らず
• IgG1 Fc-engineered (Atezolizumab) : ADCC を意図的に抑制した N297A mutation 等で T 細胞依存的 anti-tumor のみを残す設計。IMpower 系列で確立
• IgG1 Fc-modified (Durvalumab) : 同様に ADCC 低下、PACIFIC / CASPIAN / AEGEAN で確立
• IgG4 (Sugemalimab): ADCC 弱、複合体形成の immunogenicity

Resistance (Socinski et al. NEnglJMed 2018 サブ解析でも示された heterogeneity):

• IFN-γ pathway 異常 (JAK1/2 LOF), β2-microglobulin / MHC-I loss
• MDSC 主導 myeloid 抑制 (IMpower150 で bevacizumab 上乗せの rationale)
• PD-L1 IHC アッセイ間不一致 (22C3 / 28-8 / SP263 / SP142) — SP142 (Atezolizumab 用) は他より低値の傾向

臨床位置づけ

• Stage III NSCLC consolidation: Durvalumab (PACIFIC) が unique global standard。EGFR+ では LAURA (osimertinib) が置換、PACIFIC-2 は同時 IO+CRT で陰性
• SCLC 1L IO + chemo: Atezolizumab (IMpower133) / Durvalumab (CASPIAN) 併用が標準。両者 head-to-head なし
• NSCLC 1L IO + chemo + anti-VEGF: IMpower150 paradigm — 特に EGFR+ TKI 後 / 肝転移 / driver- で第一選択肢
• PD-1 inhibitor との使い分け: 直接比較試験は限定的 (INSIGNA 待ち)、選択は適応・投与スケジュール・制度的可用性で決定。ATEZO は 1680 mg Q4W、Durvalumab は 1500 mg Q4W (体重非依存)
• Driver+ NSCLC: EGFR / ALK+ では 1L IO 単剤 / +化療効果限定だが、Nogami et al. JThoracOncol 2022 / Nogami et al. JThoracOncol 2022 によれば IMpower150 ABCP は EGFR-mutant TKI 後でも benefit
• 周術期: AEGEAN (durvalumab)、IMpower010 (adjuvant atezolizumab) が選択肢

Open Questions

• anti-PD-L1 vs anti-PD-1 efficacy 差: 直接比較試験 (INSIGNA 等) の結果待ち
• Stage III consolidation の sequencing: Concurrent IO+CRT (PACIFIC-2 陰性) vs sequential consolidation の最適化
• Driver+ stage III: LAURA (Osi consolidation EGFR+) が PACIFIC を置換するか
• SCLC IO の効果限界: Durvalumab+Tremelimumab dual IO (CASPIAN 系) の OS benefit は限定的、新規モダリティとの併用
• PD-L1 IHC 不一致: 22C3 / 28-8 / SP263 / SP142 のクロスバリデーションと臨床判断

重要論文 Top 10

1. ★★★★★ Antonia et al. NEnglJMed 2017 — PACIFIC — Stage III consolidation 標準化、PFS HR 0.52
2. ★★★★★ Antonia et al. NEnglJMed 2018 — PACIFIC OS update、HR 0.68 / 5-yr OS 42.9%
3. ★★★★★ Socinski et al. NEnglJMed 2018 — IMpower150 — atezo+bev+chemo paradigm、EGFR+ / 肝転移でも benefit
4. ★★★★★ Horn et al. NEnglJMed 2018 — IMpower133 SCLC 1L IO+chemo 標準化、OS HR 0.70
5. ★★★★ Felip et al. Lancet 2021 — IMpower010 — adjuvant atezolizumab、DFS HR 0.66 (PD-L1≥1%)

関連エンティティ

• 同クラス: PD-1-inhibitor (anti-PD-1), CTLA-4 inhibitor, LAG-3 inhibitor
• 試験: PACIFIC / IMpower133 / IMpower150 / CASPIAN / AEGEAN / POSEIDON
• biomarker: PD-L1 IHC (SP263 / SP142 / 22C3 / 28-8), TMB
• ドメイン: lung-cancer-treatment, novel-cancer-modalities

関連論文

直近 30 件のみ表示中 (関連 606 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Brain metastasis

• Mavrikios et al. AnnOncol 2026 — Lung cancer brain metastases management at the dawn of personalized medicine are we ready to break the barriers

Basic-Immunotherapy

• Kamigaichi et al. CancerImmunolImmunother 2026 — Immunological impact of tumor-draining lymph node dissection on systemic th1-like CD4+ T cells in patients with
• Wang et al. Cell 2026 — A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers

Basic-Neutrophil and myeloid cell

• Lin et al. CancerDiscov 2026 — Arachidonic acid metabolism in PMN-MDSCs suppresses antitumor capacity of T cells in KRAS-mutant cholangiocarcinoma
• Hao et al. CellRepMed 2026 — Non-genetically reprogrammed meta-neutrophils potentiate chemo-immunotherapy against lung metastatic triple-negative

Basic-Oncogene and genetics

• Yap et al. Cell 2026 — Targeting genomic instability in cancer

Basic-Others

• Osarogiagbon et al. AmSocClinOncolEducBook 2026 — Optimal use of targeted therapy and immunotherapy in early-stage, resectable non-small cell lung cancer
• ODwyer et al. BMJOncol 2026 — Treatment of oligometastatic lung cancers new data, new drivers, new approaches
• Li et al. CancerImmunolRes 2026 — Peripheral th17 immune signature associates with excellent response to anti-PD1anti-PD-L1 therapy across solid tumors
• Wang et al. Carcinogenesis 2026 — Camrelizumab, apatinib and radiotherapy in locally advanced, unresectable
• Li et al. Cell 2026 — Cellular architecture and neighborhood-informed virtual spatial tumor profiling from histopathology
• Quail et al. Cell 2026 — Cancer ecosystems a dynamic interplay across scales
• Song et al. Cell 2026 — Hijacking ERAD for targeted degradation of transmembrane proteins

Basic-Tumor microenvironment

• Subudhi et al. Cell 2026 — Targeting angiogenesis lessons from 25 years of normalizing tumor vasculature

Clinical-NSCLC-Driver negative

• Chien et al. CancerImmunolImmunother 2026 — Smoking-associated modulation of gut microbiota shapes response to immune checkpoint inhibitors in non-small cell lun…
• Shimizu et al. CancerSci 2026 — Atezolizumab + chemotherapy in older patients with lung cancer in japan
• Marinelli et al. CancerTreatRev 2026 — PD-(l)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy A
• Li et al. FrontImmunol 2026 — The application and challenges of immune checkpoint inhibitors in lung cancer therapy

Clinical-NSCLC-Driver-Other

• Canaslan et al. CritRevOncolHematol 2026 — From G12C to pan-RAS the expanding therapeutic landscape of KRAS-mutant NSCLC

Clinical-NSCLC-EGFR

• Vuong et al. CancerCell 2026 — Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma
• Niu et al. FrontImmunol 2026 — Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following

Clinical-NSCLC-HER2

• Tillman et al. CancerCell 2026 — Reimagining HER2 therapy bridging oncogene addiction and immune modulation

Clinical-Novel modalities

• Jee et al. CancerDiscov 2026 — Deconvolving SARS-CoV-2 mRNA vaccine impact on immunotherapy-related survival

Clinical-Others

• Cowzer et al. ClinCancerRes 2026 — Molecular and clinical determinants of targeted therapy treatment in biliary tract cancer
• Li et al. FrontImmunol 2026 — Effect of histology on the efficacy of first-line immune checkpoint inhibitors in advanced non-small cell lung cancer a

Clinical-SCLC

• Sethakorn et al. Cancer 2026 — The future promise of antibody-drug conjugates in extensive-stage small cell lung cancer
• Hao et al. CancerCommun(Lond) 2026 — Serplulimab plus chemotherapy, with or without HLX04, versus chemotherapy as first-line treatment for nonsquamous NSCLC
• Trotta et al. Cell 2026 — Excessive vascular integrity restricts anti-tumor immunity
• Guan et al. CritRevOncolHematol 2026 — Overcoming immunotherapy resistance in extensive-stage small cell lung cancer insights into mechanisms and therapeutic
• Dai et al. CurrTreatOptionsOncol 2026 — Addressing unmet needs in the management of small cell lung cancer treatment of brain metastases, quality of life, and